A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to
evaluate the efficacy, safety, PK, PD and immunogenicity of CM310 in patients with
moderate-to-severe atopic dermatitis.
The study consists of an up-to-4-week screening period, a 16-week double-blind treatment
period, a 36-week maintenance treatment period, and a 8-week safety follow-up period.